Aptevo Europe

Aptevo Europe is the European subsidiary of Aptevo Therapeutics, a clinical-stage biotechnology company focused on developing next-generation immuno-oncology therapeutics. The company leverages its proprietary ADAPTIR and ADAPTIR-FLEX platforms to create bispecific and trispecific antibodies that engage the immune system to target cancer cells more effectively. Its lead candidate, mipletamig (APVO436), is a bispecific T-cell engager currently in Phase 1b/2 clinical trials for acute myeloid leukemia. Additionally, the company is advancing ALG.APV-527 in collaboration with Alligator Bioscience for the treatment of solid tumors. Aptevo's technology is designed to provide targeted immune activation while maintaining a favorable safety profile, addressing significant unmet needs in oncology.